Publicaciones científicas sobre los diagnósticos no invasivos de BioPredictive

Estudios revisados por pares que validan los diagnósticos por análisis de sangre de BioPredictive para enfermedades hepáticas — desde cohortes de desarrollo pioneras hasta metaanálisis a largo plazo.

7/434 Publicaciones

Overweight Borrar todo
  1. Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study.

    Codjia T et al. · Obes Surg · 2021

    FibroTest NashTest SteatoTest Metabolic

  2. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021

    FibroTest NashTest SteatoTest Metabolic

  3. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015

    SteatoTest Metabolic

  4. [The prevalence of liver and gallbladder pathologies in overweight and obese patients].

    Popova IR et al. · Klin Med (Mosk) · 2012

    ActiTest FibroTest NashTest SteatoTest +1

  5. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication Review

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008

    ActiTest AshTest FibroTest NashTest +6

  6. FibroMAX: towards a new universal biomarker of liver disease? Review

    Morra R et al. · Expert Rev Mol Diagn · 2007

    ActiTest AshTest FibroTest NashTest +7

  7. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases.

    Coco B et al. · J Viral Hepat · 2007

    FibroTest Alcohol HBV HCV +1

Mostrando la lista completa de resultados. La página se renderiza en el servidor y no está paginada.